Eli Lilly and - LLY Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 12 month price objectives for Eli Lilly and's shares. Their LLY share price forecasts range from $278.00 to $444.00. On average, they expect the company's share price to reach $382.05 in the next year. This suggests a possible upside of 14.2% from the stock's current price.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

Eli Lilly and's stock was trading at $365.84 at the start of the year. Since then, LLY shares have decreased by 8.5% and is now trading at $334.60.
View the best growth stocks for 2023 here.

Eli Lilly and saw a increase in short interest in March. As of March 15th, there was short interest totaling 8,120,000 shares, an increase of 19.2% from the February 28th total of 6,810,000 shares. Based on an average daily volume of 3,020,000 shares, the days-to-cover ratio is presently 2.7 days. Currently, 1.0% of the shares of the company are sold short.
View Eli Lilly and's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 27th 2023.
View our LLY earnings forecast.

Eli Lilly and will be holding an earnings conference call on Thursday, April 27th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings results on Thursday, February, 2nd. The company reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.26. The company earned $7.30 billion during the quarter, compared to the consensus estimate of $7.39 billion. Eli Lilly and had a net margin of 21.88% and a trailing twelve-month return on equity of 73.61%. The company's revenue was down 8.7% on a year-over-year basis. During the same quarter last year, the business earned $2.49 earnings per share.
Read the conference call transcript.

Eli Lilly and declared a quarterly dividend on Monday, December 12th. Shareholders of record on Wednesday, February 15th will be paid a dividend of $1.13 per share on Friday, March 10th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 1.35%. The ex-dividend date of this dividend is Tuesday, February 14th. This is a positive change from the stock's previous quarterly dividend of $0.98.
Read our dividend analysis for LLY.

ETFs with the largest weight of Eli Lilly and (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco Dynamic Pharmaceuticals ETF (PJP), Health Care Select Sector SPDR Fund (XLV), VanEck Pharmaceutical ETF (PPH), iShares U.S. Healthcare ETF (IYH), iShares MSCI USA Momentum Factor ETF (MTUM) and Fidelity MSCI Health Care Index ETF (FHLC).

Eli Lilly and (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 1.34%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 65.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 39.07% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

Eli Lilly and announced that its board has approved a stock buyback program on Monday, May 3rd 2021, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Eli Lilly and issued an update on its FY23 earnings guidance on Thursday, February, 2nd. The company provided EPS guidance of $8.35-$8.55 for the period, compared to the consensus EPS estimate of $8.31. The company issued revenue guidance of $30.3-$30.8 billion, compared to the consensus revenue estimate of $30.57 billion.

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by a number of institutional and retail investors. Top institutional investors include Lilly Endowment Inc. (10.83%), PNC Financial Services Group Inc. (5.48%), Price T Rowe Associates Inc. MD (2.39%), Geode Capital Management LLC (1.55%), Morgan Stanley (1.27%) and Jennison Associates LLC (1.10%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes and Stephen F Fry.
View institutional ownership trends.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $334.60.

Eli Lilly and (NYSE:LLY) has a market capitalization of $317.97 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $6.90 on an earnings per share basis.

The company employs 39,000 workers across the globe.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.